Generic Medicine Info
May be taken with or without food.
Special Precautions
Patient with history of psychosis, depression or behavioural problems; myoclonic seizures. Not indicated as 1st-line agent for complex partial seizures. Not recommended in patients with pre-existing visual field defects. Avoid abrupt withdrawal. Renal impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness or visual field defects, if affected, do not drive or operate machinery. Monitoring Parameters Perform ophthalmologic examination (e.g. dilated indirect ophthalmoscopy of the retina, visual acuity, visual field) at baseline (no later than 4 weeks after initiation), periodically (every 3 months) during therapy, and 3-6 months after discontinuation of therapy. Monitor Hb, haematocrit, weight gain, oedema; signs of visual defect, neurotoxicity, peripheral neuropathy, fluid retention. Observe for clinical worsening, suicidality, or unusual changes in behaviour and excessive sedation.
Adverse Reactions
Significant: Visual field defects, risk for permanent vision loss, anaemia, CNS depression, oedema, peripheral neuropathy, suicidal ideation and behaviour, weight gain. Eye disorders: Blurred vision, diplopia, nystagmus. Gastrointestinal disorders: Abdominal pain, nausea, vomiting. General disorders and administration site conditions: Fatigue, irritability. Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Somnolence, headache, dizziness, paraesthesia, tremor. Psychiatric disorders: Agitation, aggression, nervousness, depression, paranoid reaction, insomnia, disturbance in attention and memory impairment. Skin and subcutaneous tissue disorders: Alopecia.
Drug Interactions
May exacerbate sedative effect with clonazepam.
CIMS Class
ATC Classification
N03AG04 - vigabatrin ; Belongs to the class of fatty acid derivatives antiepileptic.
Disclaimer: This information is independently developed by CIMS based on vigabatrin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in